|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/10/22 AVROBIO, Inc. 8-K:5,9 6/08/22 11:205K ActiveDisclosure/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 35K 2: EX-10.1 Material Contract HTML 16K 6: R1 Document and Entity Information HTML 51K 9: XML IDEA XML File -- Filing Summary XML 12K 7: XML XBRL Instance -- avro-8k_20220608_htm XML 15K 8: EXCEL IDEA Workbook of Financial Reports XLSX 6K 4: EX-101.LAB XBRL Labels -- avro-20220608_lab XML 62K 5: EX-101.PRE XBRL Presentations -- avro-20220608_pre XML 38K 3: EX-101.SCH XBRL Schema -- avro-20220608 XSD 18K 10: JSON XBRL Instance as JSON Data -- MetaLinks 13± 20K 11: ZIP XBRL Zipped Folder -- 0001564590-22-022999-xbrl Zip 13K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM i 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): i June 8, 2022
i AVROBIO, INC.
(Exact name of registrant as specified in its charter)
|
i Delaware |
i 81-0710585 |
|
|
(State or other jurisdiction |
(Commission |
(I.R.S. Employer |
i One Kendall Square
i Building 300, i Suite 201
i Cambridge,
i MA i 02139
(Address of principal executive offices, including zip code)
i (617) i 914-8420
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
i ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
i ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
i ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
i ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading symbol(s) |
|
Name of each exchange on which registered |
|
i Common Stock, $0.0001 par value per share |
|
i AVRO |
|
i Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company i ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. i ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 8, 2022, AVROBIO, Inc. (the “Company”) held its previously announced 2022 Annual Meeting of Stockholders (the “Meeting”), at which a quorum was present. The proposals voted on at the Meeting and the final voting results for each proposal are as follows:
1. The Company’s stockholders elected the three director nominees listed below to serve as Class I directors until the Company’s 2025 annual meeting of stockholders, with the votes cast as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Director Nominee |
|
Votes For |
|
|
Votes Withheld |
|
|
Broker Non-Votes |
|
|||
|
Gail Farfel, Ph.D. |
|
20,123,180 |
|
|
|
6,314,307 |
|
|
|
7,438,917 |
|
|
|
Christopher Paige, Ph.D. |
|
20,383,092 |
|
|
|
6,054,395 |
|
|
|
7,438,917 |
|
|
|
Philip Vickers, Ph.D. |
|
20,717,963 |
|
|
|
5,719,524 |
|
|
|
7,438,917 |
|
|
2. The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022, with the votes cast as follows:
|
Votes For |
|
Votes Against |
|
Abstentions |
|
Broker Non-Votes |
|
33,776,363 |
|
57,906 |
|
42,135 |
|
— |
3. The Company’s stockholders approved an amendment to the AVROBIO, Inc. 2018 Stock Option and Incentive Plan, with the votes cast as follows:
|
Votes For |
|
Votes Against |
|
Abstentions |
|
Broker Non-Votes |
|
19,689,955 |
|
6,688,108 |
|
59,424 |
|
7,438,917 |
Item 9.01Financial Statements and Exhibits
(d) Exhibits
|
10.1 |
|
Second Amendment to the AVROBIO, Inc. 2018 Stock Option and Incentive Plan |
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
AVROBIO, INC. |
||||
|
Date: June 10, 2022 |
By: |
/s/ Geoff MacKay |
|
|
|
|
|
|
|
|||
|
|
|
President and Chief Executive Officer |
|
||
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 12/31/22 | ||||
| Filed on: | 6/10/22 | 4 | ||
| For Period end: | 6/8/22 | 3, 4, DEF 14A | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/15/24 AVROBIO, Inc. S-4/A 91:17M Donnelley … Solutions/FA 3/26/24 AVROBIO, Inc. S-4/A 3/25/24 89:18M Donnelley … Solutions/FA 3/14/24 AVROBIO, Inc. 10-K 12/31/23 80:9.4M Donnelley … Solutions/FA 2/14/24 AVROBIO, Inc. S-4 91:25M Donnelley … Solutions/FA 3/23/23 AVROBIO, Inc. 10-K 12/31/22 82:10M Donnelley … Solutions/FA 11/08/22 AVROBIO, Inc. S-3 8:1.8M Broadridge Fin’l So… Inc 8/09/22 AVROBIO, Inc. S-8 8/09/22 4:62K Broadridge Fin’l So… Inc 8/09/22 AVROBIO, Inc. 10-Q 6/30/22 65:7.3M Donnelley … Solutions/FA |